Liquidity and going-concern risk
Management says current cash is not sufficient to fund operations and development.
- Scope
- Operations, clinical trials, commercialization
- Materiality
- high
Femasys Inc
Femasys Inc. is a U.S.-based medical technology company developing and commercializing women’s health products, with current focus on FemaSeed and its investigational product FemBloc. The company is still in a development-and-commercialization phase, funding clinical, regulatory, manufacturing, and sales efforts while it works to expand adoption and obtain approval for its pipeline.
−752,0 %
62,0 %
−812,3 %
+40,8 %
4.53
2.95
| % | |
|---|---|
| Commercial women’s health products | 35% Currently marketed products and related commercialization efforts, including FemaSeed. |
| Pipeline product development | 45% Clinical and regulatory development of FemBloc and future product candidates. |
| Manufacturing and supply chain | 10% Production, sourcing, and supply support needed to make and ship products. |
| Sales and marketing | 10% Commercial organization and market-building activities for current and future products. |
The company sells to healthcare customers and distributors that buy women’s health products for clinical use and resale...
- U.S. healthcare customersprimary
Buy current products shipped directly in the U.S.; they value availability, clinical utility, and reliable fulfillment.
- International distributorssecondary
Purchase products for resale under EX-Works terms and extend the company’s reach outside the U.S.
- Physicians and clinicsprimary
Influence adoption of FemaSeed and potential FemBloc use by choosing products for patient care.
- Future FemBloc marketemerging
Represents the addressable customer base if FemBloc clears regulatory review and commercialization.
Femasys is headquartered in the United States and appears operationally centered there, with direct U.S...
- •Headquartered and primarily operated in the United States
- •Direct U.S. shipments are a core part of current sales
- •International distributors support non-U.S. market access
- •FDA review is critical for U.S. product candidate FemBloc
- •No country revenue split was disclosed in the excerpts
The company’s near-term strategy is to fund and complete the pivotal trial for FemBloc while continuing...
01
Complete FemBloc pivotal trialshort-term
Clinical evidence is required to support approval and future commercialization.
02
Secure additional financingshort-term
Cash on hand is not sufficient to sustain operations and development plans.
03
Scale commercialization of FemaSeedmedium-term
Current product sales help establish the platform and support future adoption.
Femasys faces substantial going-concern and financing risk because management states cash is insufficient to sustain...
Clinical and regulatory approval risk
FemBloc depends on successful pivotal trial results and FDA review.
- Scope
- FemBloc pipeline
- Materiality
- high
Nasdaq delisting risk
The company received deficiency notices tied to continued listing requirements.
- Scope
- Capital markets access and stock liquidity
- Materiality
- medium
Commercialization and adoption risk
Revenue depends on physician, clinic, and distributor uptake of products.
- Scope
- FemaSeed and future FemBloc sales
- Materiality
- medium
Point-in-time revenue recognition
Quarterly revenue comparability
Shipping terms and transfer of control
Revenue cut-off and returns handling
Stock-based compensation and convertible note amortization
Net loss and operating expense presentation
Going-concern and financing assumptions
Financial statement estimates and disclosure risk
: 28.4.2026